Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
A loss of -1.850% shows a downward development for Pacira Pharmaceuticals.
Our community is currently high on Pacira Pharmaceuticals with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 30 € shows a positive potential of 41.51% compared to the current price of 21.2 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | -1.850% | -9.402% | -4.505% | 12.766% | -1.852% | -39.429% | -58.431% |
| Supernus Pharmaceuticals | -1.060% | -7.882% | -10.526% | 15.432% | -13.023% | 30.769% | 66.964% |
| Corcept Therapeutics Inc. | -1.920% | -8.713% | 16.987% | 54.861% | 36.970% | 229.789% | 414.615% |
| Collegium Pharmaceutical Inc | 0.000% | -1.282% | -5.521% | 21.260% | -25.604% | 55.556% | 79.070% |
Comments
Pacira BioSciences (PCRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (PCRX) had its price target raised by Needham & Company LLC from $30.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat